2020
DOI: 10.1038/s41598-020-66018-5
|View full text |Cite
|
Sign up to set email alerts
|

Antitumor effect of a WEE1 inhibitor and potentiation of olaparib sensitivity by DNA damage response modulation in triple-negative breast cancer

Abstract: Due to its regulation of CDK1/2 phosphorylation, WEE1 plays essentially roles in the regulations of G2/M checkpoint and DNA damage response (DDR). WEE1 inhibition can increase genomic instability by inducing replication stress and G2/M checkpoint inactivation, which result in increased cellular sensitivity to DNA damaging agents. We considered an increase in genomic instability induced by WEE1 inhibition might be used to augment the effects of drugs targeting DNA repair protein. Typically, PARP inhibitors are … Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

1
38
0

Year Published

2020
2020
2024
2024

Publication Types

Select...
7
1
1

Relationship

0
9

Authors

Journals

citations
Cited by 59 publications
(39 citation statements)
references
References 41 publications
1
38
0
Order By: Relevance
“…The single-agent anti-tumor activity of adavosertib has been shown in multiple cancer cell lines (7)(8)(9) and in both TP53-intact and -deficient human tumor xenograft models (7). Adavosertib potentiates the activity of other DNA damage-inducing agents in preclinical models (10)(11)(12)(13), which has prompted several recent clinical trials (14)(15)(16)(17)(18). Adavosertib also acts as a radiosensitizer, enhancing radiation-induced DNA damage in vivo (19).…”
Section: Introductionmentioning
confidence: 99%
“…The single-agent anti-tumor activity of adavosertib has been shown in multiple cancer cell lines (7)(8)(9) and in both TP53-intact and -deficient human tumor xenograft models (7). Adavosertib potentiates the activity of other DNA damage-inducing agents in preclinical models (10)(11)(12)(13), which has prompted several recent clinical trials (14)(15)(16)(17)(18). Adavosertib also acts as a radiosensitizer, enhancing radiation-induced DNA damage in vivo (19).…”
Section: Introductionmentioning
confidence: 99%
“…Combination of AZD1775 with a DNA-damaging chemotherapy agent has shown increased efficacy of both drugs in various preclinical cancer models (28,(55)(56)(57). In breast cancer, targeting WEE1 with AZD1775 has been recently investigated by others as a promising strategy in combination therapeutic approaches in different subtypes of the disease, particularly in preclinical models of TNBC (28,30,(58)(59)(60). In HER2-positive breast cancer cells models, treatment with AZD1775 overcomes resistance to standard-of-care therapy trastuzumab, a monoclonal antibody that targets HER2 (43).…”
Section: Discussionmentioning
confidence: 99%
“…Particularly in breast cancer, Murrow et al used a RNAi screen of the human tyrosine kinome, to identify WEE1 as a potential therapeutic target in triple-negative breast cancer cells that lack ER, progesterone receptor [PR] or HER2 (27). In recent years, a number of preclinical studies have focused on understanding the functionality of WEE1 in breast cancer cells, particularly those with defective cell cycle regulation (28)(29)(30).…”
Section: Introductionmentioning
confidence: 99%
“…Several additional drugs exhibited subtype specificity that matched their targeted clinical indication: relative to other subtypes, HR + cell lines were more sensitive to the AKT inhibitors AZD5363 and ipatasertib, and mTOR inhibitors everolimus, AZD2014 and LY302341; TNBC cell lines were more sensitive to the WEE1 inhibitor adavosertib, the ATR inhibitor AZD6738, and the PARP inhibitors rucaparib and olaparib. [45][46][47] One striking feature of these data is that NM lines were not more resistant overall than cancer lines; this was true of pre-clinical compounds and drugs approved by the FDA for treatment of breast cancer (Fig. 4c, in bold).…”
Section: Using Dye Drop To Systematically Screen Small Molecule Drugs In Breast Cancer Cell Linesmentioning
confidence: 91%